# Publication

## [Diagnostic Performance of LIVERFASt as a Non-invasive Liver Fibrosis Test: Data from Three Cohorts of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease](/content/diagnostic-performance-of-liverfast-as-a-non-invasive-liver-fibrosis-test-data-from-three-cohorts-of-patients-with-metabolic-dysfunction-associated-steatotic-liver-disease-2/index.html)

Aim: This study evaluates the diagnostic performance of the novel blood-based device, LIVERFASt to detect fibrosis stages in patients with metabolic […]

## [Non- Invasive Initiation & Monitoring of Resmetirom (RT) Therapy Using LIVERFASt, FIB-4, and VCTE in MASH Patients](/content/noninvasive-initiation-and-monitoring-of-resmetirom-rt-therapy-in-mash-patients/index.html)

The poster presents a retrospective study on the use of non-invasive tests (NITs) to initiate and monitor Resmetirom (RT) therapy

## [LIVERFASt (L-FAST) Identifies Advanced (F3F4, AF) and Clinically Significant Fibrosis (F2-F4, CSF) in MASLD Patients](/content/liverfast-l-fast-identifies-advanced-f3f4-af-and-clinically-significant-fibrosis-f2-f4-csf-in-masld-patients/index.html)

In a biopsy-validated cohort of MASLD patients (n=399, with 235 T2D), combining LIVERFASt with Fibroscan correctly identified 95% of F3–F4

## [The Utility of Non-Invasive Tests (NITs) – LIVERFASt, FIB4 and VCTE (Fibroscan) in MASH Patients](/content/the-utility-of-noninvasive-tests-nits-liverfast-fib4-and-vcte-fibroscan-in-mash-patients/index.html)

This publication evaluates the real-world use of non-invasive tests (LIVERFASt, FIB-4, and VCTE) in monitoring MASH patients undergoing resmetirom therapy.

## [Association between Psoriasis Severity & Steatosis Measured by AI-based Algorithm (LIVERFAStTM)](/content/association-between-psoriasis-severity-steatosis-measured-by-ai-based-algorithm-liverfasttm/index.html)

This publication explores the relationship between psoriasis severity and liver steatosis using the AI-based LIVERFASt tool. Patients with more severe

## [Combination of LIVERSTAT (LST) and Fibroscan (LSM) Outperforms FIB-4 and LSM for MASLD Advanced Fibrosis](/content/combination-of-liverstat-and-fibroscan-outperforms-fib-4-and-lsm/index.html)

Combining LIVERSTAT with Liver Stiffness Measurement (LSM) more effectively identifies advanced liver fibrosis (F3F4) in patients with MASLD, particularly those

## [Combination of LIVERfASt (LF) & Liver Stiffness Measurement (LSM) in patients with type 2 diabetes (T2D)](/content/enhanced-liver-fibrosis-detection-in-t2d/index.html)

Combining LIVERFASt with Liver Stiffness Measurement (LSM) is more effective than FIB-4 & LSM for identifying advanced liver fibrosis in

## [LIVERFASt: Non-Invasive Liver Assessment for Chronic Hepatitis B & Diabetes](/content/liverfast-non-invasive-liver-assessment-for-chronic-hepatitis-b-diabetes/index.html)

This publication introduces LIVERFASt, a non-invasive biomarker for predicting liver steatosis and fibrosis in patients with chronic Hepatitis B and

## [Retrospective cross sectional evaluation of the LIVERFASt Test for staging liver fibrosis in MASLD patients in NIDDK studies’ populations using liver biopsy](/content/retrospective-cross-sectional-evaluation-of-the-liverfast-test-for-staging-liver-fibrosis-in-masld-patients-in-niddk-studies-populations-using-liver-biopsy/index.html)

MASLD affects more than 25% of subjects of the general population and can progress to advanced fibrosis (AF) and cirrhosis

## [Application of LIVERFASt Biomarkers to Evaluate Longitudinal Hepatic Fibrosis and Inflammation after HCV cure](/content/application-of-liverfast-biomarkers-to-evaluate-longitudinal-hepatic-fibrosis-and-inflammation-after-hcv-cure/index.html)

Hepatitis C virus (HCV) infection is a common cause of both liver cirrhosis and hepatocellular carcinoma. Successful Direct antiviral agents